283 related articles for article (PubMed ID: 31772119)
41. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.
Kawai H; Ando K; Maruyama D; Yamamoto K; Kiyohara E; Terui Y; Fukuhara N; Miyagaki T; Tokura Y; Sakata-Yanagimoto M; Igarashi T; Kuroda J; Fujita J; Uchida T; Ishikawa T; Yonekura K; Kato K; Nakanishi T; Nakai K; Matsunaga R; Tobinai K
Cancer Sci; 2021 Jun; 112(6):2426-2435. PubMed ID: 33792128
[TBL] [Abstract][Full Text] [Related]
42. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
43. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
44. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
[TBL] [Abstract][Full Text] [Related]
45. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
46. A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
Reiman T; Savage KJ; Crump M; Cheung MC; MacDonald D; Buckstein R; Couban S; Piliotis E; Imrie K; Spaner D; Shivakumar S; Kuruvilla J; Villa D; Shepherd LE; Skamene T; Winch C; Chen BE; Hay AE
Leuk Lymphoma; 2019 Apr; 60(4):912-919. PubMed ID: 30301414
[TBL] [Abstract][Full Text] [Related]
47. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
[TBL] [Abstract][Full Text] [Related]
48. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
[TBL] [Abstract][Full Text] [Related]
49. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Horwitz SM; Hymes K; Goy A; Hernandez-Ilizaliturri FJ; Feldman T; Wegner B; Myskowski PL
Ann Oncol; 2014 Jan; 25(1):206-10. PubMed ID: 24285015
[TBL] [Abstract][Full Text] [Related]
50. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
51. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Eyre TA; Collins GP; Gupta A; Coupe N; Sheikh S; Whittaker J; Wang LM; Campo L; Soilleux E; Tysoe F; Cousins R; La Thangue N; Folkes LK; Stratford MRL; Kerr D; Middleton MR
Cancer; 2019 Jan; 125(1):99-108. PubMed ID: 30332497
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
53. Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular helper phenotype after allogeneic hematopoietic cell transplantation.
Tao K; Inamoto Y; Furukawa H; Hosoba R; Takeda W; Maeshima A; Aoki J; Ito A; Tanaka T; Kim SW; Makita S; Fukuhara S; Kogure Y; Kataoka K; Izutsu K; Fukuda T
Int J Hematol; 2023 Aug; 118(2):292-298. PubMed ID: 36807258
[TBL] [Abstract][Full Text] [Related]
54. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
55. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
56. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
[TBL] [Abstract][Full Text] [Related]
57. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL; Salles G; Moskowitz AJ; Santoro A; Mehta A; Barr PM; Mehta-Shah N; Collins GP; Ansell SM; Brody JD; Domingo-Domenech E; Johnson NA; Cunningham D; Ferrari S; Lisano J; Krajewski J; Wen R; Akyol A; Crowe R; Savage KJ
Blood Adv; 2024 May; 8(10):2400-2404. PubMed ID: 38531062
[No Abstract] [Full Text] [Related]
58. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.
Duvic M; Kim YH; Zinzani PL; Horwitz SM
Clin Cancer Res; 2017 Jul; 23(14):3552-3556. PubMed ID: 28167509
[No Abstract] [Full Text] [Related]
59. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
[TBL] [Abstract][Full Text] [Related]
60. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]